Patent application EP19171455A (EP), filed 2019-04-26
Publication number: EP3730617A1
Title: NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL
Abstract: [0001]    The invention relates to nucleic acid products that interfere with complement component C3 gene expression or inhibit its expression. The nucleic acids are preferably for use as treatment, prevention or reduction of risk of suffering from complement component C3 associated diseases, disorders or syndromes, particularly C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), Lupus nephritis, IgA nephropathy (IgAN), Cold Agglutinin Disease (CAD), Myasthenia gravis (MG), and Primary Membranous Nephropathy.
IPC codes: C12N  15/   113            A I
Claims: number: 1
text: A double-stranded nucleic acid for inhibiting expression of complement component C3, wherein the nucleic acid comprises a first strand and a second strand, wherein the first strand sequence comprises a sequence of at least 15 nucleotides differing by no more than 3 nucleotides from any one of the sequences SEQ ID NO: 361, 95, 111, 125, 131, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 97, 99, 101, 103, 105, 107, 109, 113, 115, 117, 119, 121, 123, 127, 129 or 133.
number: 2
text: A double-stranded nucleic acid that is capable of inhibiting expression of complement component C3 for use as a medicament.
number: 3
text: The nucleic acid of any of the preceding claims, wherein the first strand and the second strand form a duplex region from 17-25 nucleotides in length.
number: 4
text: The nucleic acid of any of the preceding claims, wherein the nucleic acid mediates RNA interference.
number: 5
text: The nucleic acid of any of the preceding claims, wherein at least one nucleotide of the first and/or second strand is a modified nucleotide, preferably a non-naturally occurring nucleotide such as a 2'-F modified nucleotide.
number: 6
text: The nucleic acid of any of the preceding claims, wherein at least nucleotides 2 and 14 of the first strand are modified by a first modification, the nucleotides being numbered consecutively starting with nucleotide number 1 at the 5' end of the first strand.
number: 7
text: The nucleic acid of any of the previous claims, wherein the first strand has a terminal 5' (E)-vinylphosphonate nucleotide at its 5' end.
number: 8
text: The nucleic acid of any of the preceding claims, wherein the nucleic acid comprises a phosphorothioate linkage between the terminal two or three 3' nucleotides and/or 5' nucleotides of the first and/or the second strand and preferably wherein the linkages between the remaining nucleotides are phosphodiester linkages.
number: 9
text: The nucleic acid of any of the preceding claims, comprising a phosphorodithioate linkage between each of the two, three or four terminal nucleotides at the 3' end of the first strand and/or comprising a phosphorodithioate linkage between each of the two, three or four terminal nucleotides at the 3' end of the second strand and/or a phosphorodithioate linkage between each of the two, three or four terminal nucleotides at the 5' end of the second strand and comprising a linkage other than a phosphorodithioate linkage between the two, three or four terminal nucleotides at the 5' end of the first strand.
number: 10
text: The nucleic acid of any of the preceding claims, wherein the nucleic acid is conjugated to a ligand.
number: 11
text: The nucleic acid of claim 10, wherein the ligand comprises (i) one or more N-acetyl galactosamine (GalNAc) moieties or derivatives thereof, and (ii) a linker, wherein the linker conjugates the at least one GalNAc moiety or derivative thereof to the nucleic acid.
number: 12
text: A composition comprising a nucleic acid of any of the previous claims and a delivery vehicle and/or a physiologically acceptable excipient and/or a carrier and/or a diluent and/or a buffer and/or a preservative and/or a further therapeutic agent selected from the group comprising an oligonucleotide, a small molecule, a monoclonal antibody, a polyclonal antibody and a peptide.
number: 13
text: A nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 for use as a medicament.
number: 14
text: A nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 for use in the prevention, decrease of the risk of suffering from, or treatment of a disease, disorder or syndrome, wherein the disease, disorder or syndrome is preferably a complement-mediated disease, disorder or syndrome.
number: 15
text: Use of a nucleic acid of any of claims 1 and 3-11 or a composition of claim 12 in the prevention, decrease of the risk of suffering from, or treatment of a disease, disorder or syndrome, wherein the disease, disorder or syndrome is preferably C3 Glomerulopathy (C3G).
Office action: search_report, dated 2020-10-28
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: US5885968A
ref_type: patent
severity: background
ref_id: EP0758904A1
ref_type: patent
severity: background
ref_id: WO2017174657A1
ref_type: patent
severity: background
ref_id: WO2019089922A1
ref_type: patent
severity: background
ref_id: - FIRE ET AL., NATURE, vol. 391, no. 6669, 19 February 1998 (1998-02-19), pages 806 - 11
ref_type: npl
severity: background
ref_id: - ELBASHIR ET AL., NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 8
ref_type: npl
severity: background
ref_id: - WATTS; COREY, JOURNAL OF PATHOLOGY, vol. 226, 2012, pages 365 379
ref_type: npl
severity: background
ref_id: - "Janeway's Immunobiology"
ref_type: npl
severity: background
ref_id: - DUBBER ET AL., BIOCONJUG. CHEM., vol. 14, no. 1, January 2003 (2003-01-01), pages 239 - 46
ref_type: npl
severity: background
ref_id: - WEIGEL, P.H., BIOCHIM. BIOPHYS. ACTA, vol. 1572, no. 2-3, 19 September 2002 (2002-09-19), pages 341 - 63
ref_type: npl
severity: background
ref_id: - ISHIBASHI,S., J BIOL. CHEM., vol. 269, no. 45, 11 November 1994 (1994-11-11), pages 27803 - 6
ref_type: npl
severity: background
ref_id: - BIESSEN EA ET AL., J MED CHEM., vol. 38, no. 9, 28 April 1995 (1995-04-28), pages 1538 - 46
ref_type: npl
severity: background
ref_id: - AKINC ET AL., MOL THER., vol. 18, no. 7, July 2010 (2010-07-01), pages 1357 - 64
ref_type: npl
severity: background
ref_id: - HOEVELMANN ET AL., CHEM. SCI., vol. 7, 2016, pages 128 - 135
ref_type: npl
severity: background
ref_id: - NAIR ET AL., J. AM. CHEM. SOC., vol. 136, no. 49, 2014, pages 16958 - 1696
ref_type: npl
severity: background
ref_id: - PRAKASH, NUCLEIC ACIDS RES., vol. 43, no. 6, 2015, pages 2993 - 3011
ref_type: npl
severity: background
ref_id: - HARASZTI, NUCLEIC ACIDS RES., vol. 45, no. 13, 2017, pages 7581 - 7592
ref_type: npl
severity: background
ref_id: WO2015089368A2
ref_type: patent
severity: background
ref_id: US2003096775A1
ref_type: patent
severity: background
ref_id: - REKA A. HARASZTI ET AL: "5'-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo", NUCLEIC ACIDS RESEARCH, vol. 45, no. 13, 7 June 2017 (2017-06-07), pages 7581 - 7592, XP055599779, ISSN: 0305-1048, DOI: 10.1093/nar/gkx507
ref_type: npl
severity: background
ref_id: US2003096775
ref_type: patent
severity: background
ref_id: WO2015089368
ref_type: patent
severity: novelty_destroying
ref_id: - REKA A. HARASZTI ET AL, "5'-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo", NUCLEIC ACIDS RESEARCH, (20170607), vol. 45, no. 13, doi:10.1093/nar/gkx507, ISSN 0305-1048, pages 7581 - 7592, XP055599779 [YD] 7 * abstract * * page  7582, column  l, line  2  - line  5 *
ref_type: npl
severity: obviousness
Final disposition: pending (2020-10-28)